Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors

(2017) F. Atzori et al.   JOURNAL OF CLINICAL ONCOLOGY

NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer

(2017) M. N. Pollak et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

(2017) J. Jassem et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

(2017) S. Di Cosimo et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

(2011) Vivek Subbiah et al.   PLoS One

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

(2010) A Gualberto et al.   BRITISH JOURNAL OF CANCER

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

(2010) L R Molife et al.   BRITISH JOURNAL OF CANCER

Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

(2010) A. Gualberto et al.   CLINICAL CANCER RESEARCH

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

(2010) R. Quek et al.   CLINICAL CANCER RESEARCH

Targeting insulin-like growth factor 1 receptor in sarcomas

(2010) Katia Scotlandi et al.   CURRENT OPINION IN ONCOLOGY

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies

(2010) D. Olmos et al.   MOLECULAR CANCER THERAPEUTICS

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

(2009) Daniel D. Karp et al.   Journal of Thoracic Oncology

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

(2009) A Gualberto et al.   ONCOGENE

Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine

(2009) Madeleine Hewish et al.   Recent Patents on Anti-Cancer Drug Discovery

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

(2008) J. H. Law et al.   CANCER RESEARCH

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

(2008) John SP Yuen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Commercial interest waxes for IGF-1 blockers

(2008) Randy Osborne   NATURE BIOTECHNOLOGY

The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer

(2008) P. D. Ryan et al.   ONCOLOGIST